interferon gamma increases IDO1 expression, which lowers intracellular tryptophan and fight bacterial and virus (low intracellular tryptophan directly starves intracellular chlamydia and stop them to grow up and proliferate).
"IFNG : This gene encodes a soluble cytokine that is a member of the type II interferon class. The encoded protein is secreted by cells of both the innate and adaptive immune systems. The active protein is a homodimer that binds to the interferon gamma receptor which triggers a cellular response to viral and microbial infections. Mutations in this gene are associated with an increased susceptibility to viral, bacterial and parasitic infections and to several autoimmune diseases."
So if this metabolic trap is correct, I suppose alteration in the IFNG gene would be a predisposition to ME/CFS.
sorry to quote myself but here what has been found about IFNG, CFS patients would be high IFNG producers!
However I wonder of this finding is significant, I would like to know more about polymorphism for the IFNGR1, because impairment of this receptor leads to impaired INF gamma activity
Clin Exp Rheumatol. 2006
A first study of cytokine genomic polymorphisms in CFS: Positive association of TNF-857 and IFNgamma 874 rare alleles.
Abstract
OBJECTIVE:
In the past two years we have developed a biological bank of genomic DNA, cDNA, serum and red blood cells of Italian patients with certified CFS from the two Italian referral centers for the syndrome. Recent studies have shown an imbalance in cytokine production in disease states similar to Chronic Fatigue Syndrome (CFS), such as sickness behavior, both in animals and in humans. However we notice that serum cytokine concentrations are often inconstant and degrade rapidly. With this in mind, we investigated cytokine gene polymorphisms in 80 Italian patients with CFS in order to ascertain whether in this group of patients it is possible to describe a genetic predisposition to an inflammatory response.
METHODS:
We analyzed the promoter polymorphisms of IL-10, IL-6 and the
IFNgamma 874 T/A polymorphism in intron 1 with a PCR-SSP method (Cytogen One Lambda Inc. Canoga Park, CA, U.S.A) in 54 patients and TNF-308 G/A and -857 C/T promoter polymorphisms with a PCR-RFLP method (in 54 and 80 patients respectively).
RESULTS:
There is a highly significant increase of TNF -857 TT and CT genotypes (p = 0.002) among patients with respect to controls and a significant decrease of IFN gamma low producers (A/A) (p = 0.04) among patients with respect to controls.
CONCLUSIONS:
We hypothesize that CFS patients can have a genetic predisposition to an immunomodulatory response of an inflammatory nature probably secondary to one or more environmental insults of unknown nature.